Erbitux MEtastatic Colorectal Cancer Strategy Study

NCT02484833 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

607

Enrollment

OTHER

Sponsor class

Conditions

Antineoplastic Agents

Interventions

DRUG: Cetuximab
DRUG: FOLFIRI

Sponsor

Armando Orlandi